Intravenous Infusions (XGHA:IIL) Interest Coverage: 0 (At Loss) (As of . 20)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Intravenous Infusions Interest Coverage?

Intravenous Infusions XGHA:IIL +8.86% Interest Coverage is 0 (At Loss) as of . 20. Among 688 Drug Manufacturers companies, Intravenous Infusions ranks worse than 145348.69% on this metric.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income by its Interest Expense. Intravenous Infusions's Operating Income for the six months ended in . 20 was GHS0.00 Mil. Intravenous Infusions's Interest Expense for the six months ended in . 20 was GHS0.00 Mil. did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is.

(1) Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

The historical rank and industry rank for Intravenous Infusions's Interest Coverage or its related term are showing as below:


XGHA:IIL's Interest Coverage is not ranked *
in the Drug Manufacturers industry.
Industry Median: 12.765
* Ranked among companies with meaningful Interest Coverage only.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Intravenous Infusions  (XGHA:IIL) Interest Coverage Explanation

Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.

Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .

Intravenous Infusions Interest Coverage Related Terms

Intravenous Infusions Interest Coverage Historical Data

* Premium members only.

The historical data trend for Intravenous Infusions's Interest Coverage can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

Intravenous Infusions Interest Coverage Chart

Intravenous Infusions Annual Data
Trend
Interest Coverage

Intravenous Infusions Semi-Annual Data
Interest Coverage

XGHA:IIL vs PTLF, PCYN, YBAO: Interest Coverage Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Intravenous Infusions's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Intravenous Infusions Interest Coverage vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Intravenous Infusions's Interest Coverage distribution charts can be found below:

* The bar in red indicates where Intravenous Infusions's Interest Coverage falls into.


Intravenous Infusions Interest Coverage Calculation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:

If Interest Expense is negative and Operating Income is positive, then

Interest Coverage=-1* Operating Income /Interest Expense

Else if Interest Expense is negative and Operating Income is negative, then

The company did not have earnings to cover the interest expense.

Else if Interest Expense is 0 and Long-Term Debt & Capital Lease Obligation is 0, then

The company had no debt (1).


Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Intravenous Infusions's Interest Coverage for the fiscal year that ended in . 20 is calculated as

Here, for the fiscal year that ended in . 20, Intravenous Infusions's Interest Expense was GHS0.00 Mil. Its Operating Income was GHS0.00 Mil. And its Long-Term Debt & Capital Lease Obligation was GHS0.00 Mil.

Intravenous Infusions had no debt (1).

Intravenous Infusions's Interest Coverage for the quarter that ended in . 20 is calculated as

Here, for the six months ended in . 20, Intravenous Infusions's Interest Expense was GHS0.00 Mil. Its Operating Income was GHS0.00 Mil. And its Long-Term Debt & Capital Lease Obligation was GHS0.00 Mil.

Intravenous Infusions had no debt (1).

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's Financial Strength is.

Frequently Asked Questions Learn more about Interest Coverage →
What does a Interest Coverage of 0 (At Loss) mean?
Intravenous Infusions (XGHA:IIL) has a Interest Coverage of 0 (At Loss) as of . 20. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Intravenous Infusions and its competitors. According to the industry distribution chart, Intravenous Infusions ranks #999999 out of 688 companies in the Drug Manufacturers industry.
Is Intravenous Infusions' Interest Coverage too high?
Intravenous Infusions' current Interest Coverage is 0 (At Loss). Based on the distribution chart, Intravenous Infusions ranks #999999 out of 688 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers.
How does Intravenous Infusions' Interest Coverage compare to PTLF and PCYN?
According to the Drug Manufacturers industry distribution chart, Intravenous Infusions ranks #999999 out of 688 companies for Interest Coverage. This places Intravenous Infusions in the lower half of its industry. The industry median Interest Coverage is 12.77. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Coverage for a Drug Manufacturers company?
The median Interest Coverage among Drug Manufacturers companies is 12.77, based on 688 companies in the industry. Companies in the top quartile (top 25%) have a Interest Coverage significantly above this median, while those in the bottom quartile fall well below. However, Interest Coverage should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Coverage mean?
A high Interest Coverage can signal that a stock is expensive relative to its fundamentals. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Intravenous Infusions and its competitors. For the Drug Manufacturers industry, the median Interest Coverage is 12.77 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Intravenous Infusions's current Interest Coverage is 0 (At Loss). However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Intravenous Infusions stock overvalued right now?
Intravenous Infusions (XGHA:IIL) has a current Interest Coverage of 0 (At Loss). The current Interest Coverage is 0 (At Loss). Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Coverage calculated?
Interest Coverage is calculated from a company's financial statements. For Intravenous Infusions (XGHA:IIL), the current Interest Coverage is 0 (At Loss) as of . 20. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Intravenous Infusions Business Description

Address Plot 4/7 Blk L, P.O Box KF 63, Effiduase-Koforidua, GHA
Intravenous Infusions Ltd engages in the production of intravenous infusion and small-volume injectables for therapeutic purposes. The product categories are IV fluids, giving sets, and small-volume injectables. The company earns a majority of its revenue from IV fluids. Some of the IV fluids are sodium chloride solutions, dextrose solutions, dextrose saline solutions, and dextran solutions. Small-volume injectables include pethidine injection, magnesium sulphate injection, and quinine injection. Giving sets include plain giving sets, and blood giving sets.